Humacyte Analyst Ratings
Humacyte Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2023 | 27.66% | Piper Sandler | $3.5 → $3 | Maintains | Neutral |
| 09/21/2023 | 197.87% | Cantor Fitzgerald | → $7 | Reiterates | Overweight → Overweight |
| 08/31/2023 | 155.32% | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight |
| 08/24/2023 | 155.32% | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight |
| 08/15/2023 | 580.85% | Benchmark | → $16 | Reiterates | Buy → Buy |
| 06/22/2023 | 155.32% | Cantor Fitzgerald | → $6 | Initiates Coverage On | → Overweight |
| 06/12/2023 | 580.85% | Benchmark | → $16 | Reiterates | Buy → Buy |
| 03/27/2023 | 580.85% | Benchmark | → $16 | Reiterates | → Buy |
| 07/18/2022 | 325.53% | BTIG | $12 → $10 | Maintains | Buy |
| 10/29/2021 | 623.4% | Cowen & Co. | → $17 | Initiates Coverage On | → Outperform |
| 09/24/2021 | 580.85% | Oppenheimer | → $16 | Initiates Coverage On | → Outperform |
| 09/22/2021 | 708.51% | BTIG | → $19 | Initiates Coverage On | → Buy |
| 09/16/2021 | 623.4% | Piper Sandler | → $17 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/10/2023 | 27.66% | 派珀·桑德勒 | 3.5 美元 → 3 美元 | 維護 | 中立 |
| 09/21/2023 | 197.87% | 坎託·菲茨傑拉德 | → 7 美元 | 重申 | 超重 → 超重 |
| 08/31/2023 | 155.32% | 坎託·菲茨傑拉德 | → 6 美元 | 重申 | 超重 → 超重 |
| 08/24/2023 | 155.32% | 坎託·菲茨傑拉德 | → 6 美元 | 重申 | 超重 → 超重 |
| 08/15/2023 | 580.85% | 基準 | → 16 美元 | 重申 | 購買 → 購買 |
| 06/22/2023 | 155.32% | 坎託·菲茨傑拉德 | → 6 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 06/12/2023 | 580.85% | 基準 | → 16 美元 | 重申 | 購買 → 購買 |
| 03/27/2023 | 580.85% | 基準 | → 16 美元 | 重申 | → 購買 |
| 07/18/2022 | 325.53% | BTIG | 12 美元 → 10 美元 | 維護 | 買 |
| 10/29/2021 | 623.4% | Cowen & Co. | → 17 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 9 月 24 日 | 580.85% | 奧本海默 | → 16 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 9 月 22 日 | 708.51% | BTIG | → 19 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 09/16/2021 | 623.4% | 派珀·桑德勒 | → 17 美元 | 啓動覆蓋範圍開啓 | → 超重 |
What is the target price for Humacyte (HUMA)?
Humacyte (HUMA) 的目標價格是多少？
The latest price target for Humacyte (NASDAQ: HUMA) was reported by Piper Sandler on November 10, 2023. The analyst firm set a price target for $3.00 expecting HUMA to rise to within 12 months (a possible 27.66% upside). 8 analyst firms have reported ratings in the last year.
派珀·桑德勒於2023年11月10日公佈了Humacyte（納斯達克股票代碼：HUMA）的最新目標股價。該分析公司將目標股價定爲3.00美元，預計HUMA將在12個月內升至12個月內（可能上漲27.66％）。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Humacyte (HUMA)?
分析師對Humacyte（HUMA）的最新評級是多少？
The latest analyst rating for Humacyte (NASDAQ: HUMA) was provided by Piper Sandler, and Humacyte maintained their neutral rating.
派珀·桑德勒對Humacyte（納斯達克股票代碼：HUMA）的最新分析師評級由派珀·桑德勒提供，Humacyte維持中性評級。
When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?
Humacyte（HUMA）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表、與Humacyte的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Humacyte的最新評級是在2023年11月10日發佈的，因此您應該預計下一個評級將在2024年11月10日左右公佈。
Is the Analyst Rating Humacyte (HUMA) correct?
分析師對 Humacyte (HUMA) 的評級正確嗎？
While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a maintained with a price target of $3.50 to $3.00. The current price Humacyte (HUMA) is trading at is $2.35, which is out of the analyst's predicted range.
儘管評級是主觀的並且會發生變化，但最新的Humacyte（HUMA）評級保持不變，目標股價爲3.50美元至3.00美元。Humacyte（HUMA）目前的交易價格爲2.35美元，超出了分析師的預期區間。